- Home
- FORA vs ICCC Comparison
FORA vs ICCC Comparison
Compare FORA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ICCC
- Stock Information
- Founded
- FORA 2014
- ICCC 1982
- Country
- FORA United States
- ICCC United States
- Employees
- FORA N/A
- ICCC N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- ICCC Health Care
- Exchange
- FORA Nasdaq
- ICCC Nasdaq
- Market Cap
- FORA 69.4M
- ICCC 57.4M
- IPO Year
- FORA N/A
- ICCC 1987
- Fundamental
- Price
- FORA $2.32
- ICCC $6.73
- Analyst Decision
- FORA Strong Buy
- ICCC
- Analyst Count
- FORA 1
- ICCC 0
- Target Price
- FORA $5.00
- ICCC N/A
- AVG Volume (30 Days)
- FORA 20.7K
- ICCC 17.8K
- Earning Date
- FORA 11-12-2025
- ICCC 11-12-2025
- Dividend Yield
- FORA N/A
- ICCC N/A
- EPS Growth
- FORA N/A
- ICCC N/A
- EPS
- FORA N/A
- ICCC 0.20
- Revenue
- FORA $25,031,040.00
- ICCC $28,274,756.00
- Revenue This Year
- FORA $47.82
- ICCC N/A
- Revenue Next Year
- FORA $10.11
- ICCC N/A
- P/E Ratio
- FORA N/A
- ICCC $32.84
- Revenue Growth
- FORA 18.59
- ICCC 21.75
- 52 Week Low
- FORA $1.64
- ICCC $3.38
- 52 Week High
- FORA $4.03
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- FORA 59.84
- ICCC 62.26
- Support Level
- FORA $2.20
- ICCC $6.30
- Resistance Level
- FORA $2.33
- ICCC $6.99
- Average True Range (ATR)
- FORA 0.07
- ICCC 0.31
- MACD
- FORA -0.01
- ICCC 0.07
- Stochastic Oscillator
- FORA 64.81
- ICCC 79.54
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.